Zenicor (ZENI) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 increased by 10% year-over-year to 7,043 KSEK, marking the best second quarter to date.

• Operating profit for Q2 2025 was positive at 126 KSEK, maintaining profitability during growth.

• Growth driven by new contracts in Finland and continued high usage in Region Dalarna.

• NHS approval in West Yorkshire, UK, and a major contract win in Helsinki region, Finland, strengthen international position.

Financial highlights

• Net sales Q2 2025: 7,043 KSEK (6,430 KSEK in Q2 2024), up 10% year-over-year.

• Operating profit Q2 2025: 126 KSEK (118 KSEK in Q2 2024).

• Earnings per share Q2 2025: 0.01 SEK (0.01 SEK in Q2 2024); shares outstanding increased to 13,945,215.

• Period result Q2 2025: -87 KSEK (-430 KSEK in Q2 2024).

• Cash flow from operations Q2 2025: 1,022 KSEK; period-end cash: 301 KSEK.

Outlook and guidance

• Anticipates continued growth through further contract wins, especially in Finland.

• Revenue may fluctuate due to increasing share of contract-based income.

• Focus on balancing cash flow and reducing remaining shareholder loans in coming quarters.